We scan new podcasts and send you the top 5 insights daily.
Banerjee notes FDA interest in echocardiograms with MEK inhibitors, and RAMP 301 introduced them. Even an asymptomatic patient doing well should get an echo, she says, because cardiac dysfunction can be managed by pausing the drug, treating with cardiology input, and restarting when ejection fraction improves.
Faculty consensus establishes chest CT surveillance every nine weeks for patients receiving trastuzumab deruxtecan, narrowing to six-week intervals for higher-risk patients or during ILD re-challenge. For cardiac monitoring, clinicians obtain a baseline echocardiogram followed by repeat evaluations at least every three months to catch asymptomatic declines in left ventricular ejection fraction.
Banerjee has not told patients to avoid exercise and has not seen symptomatic muscle or cardiac events from CPK elevation. She manages it by grade in her practice: pause grade 3 until recovery, then resume the same dose; grade 4 may require dose reduction or stopping.
An observed signal for cardiac dysfunction in the Lenvatinib-Belzutifan arm of a recent trial is causing concern among clinicians. The lack of detailed characterization for this toxicity makes it a significant point of discussion and an area requiring more data before the regimen's safety profile is fully understood.
While trametinib carries a ~6% risk of congestive heart failure, this specific toxicity has not been observed with the avutametinib/defactinib combination. This distinct safety profile makes the doublet a potentially safer option, especially for patients with cardiac risk or who failed trametinib due to heart issues.
When monitoring for cardiac toxicity with ADCs, assessing myocardial 'strain' via echocardiogram provides an earlier warning sign than ejection fraction (EF) alone. A change in strain, which measures the function of small muscle fibers, often precedes a drop in the overall EF, allowing for earlier intervention.
Contrary to belief that TKIs mainly worsen pre-existing issues, Nilotinib's cardiovascular toxicity can develop years into therapy, even in young patients without traditional risk factors. This implies a direct, long-term drug effect beyond just exacerbating comorbidities.
Susanna Banerjee explained that elevated creatine phosphokinase from avutometinib and defactinib represents an asymptomatic biochemical rise rather than cardiac damage or rhabdomyolysis. Trialists initially set overly strict dose interruption guidelines before recognizing patients had no corresponding muscle symptoms.
For EGFR-mutated lung cancer patients experiencing cardiac toxicity like QTc prolongation with osimertinib, lazertinib presents a viable alternative. Its lower rate of cardiac side effects allows for continued third-generation TKI therapy in a specific patient subset where osimertinib may be contraindicated.
While atrial fibrillation is a well-known risk of BTK inhibitors, the more devastating and less-discussed risk is sudden death from ventricular arrhythmias. This is an 'on-target' class effect, making AFib just the 'tip of the iceberg' of cardiovascular toxicity.
While monitoring cardiac health for safety, Solid Biosciences observed a potential efficacy signal. In young patients with low-to-normal ejection fractions, the therapy appears to reverse a downward 'drift' over time, returning them to a normal range. This suggests a long-term cardioprotective benefit, even before a formal cardiomyopathy diagnosis would typically occur.